Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05371041 · ClinicalTrials.gov registry record · NA
Tourette Deep Brain Stimulation (DBS) Target Detection & Suppression
A NA study of Tourette Syndrome, sponsored by University of Florida.
- Active
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05371041: Active NA study of Tourette Syndrome, sponsored by University of Florida.
NCT05371041 is a NA study of Tourette Syndrome that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 8 participants, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05371041, a NA study of Tourette Syndrome, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will implant and monitor 8 research subjects with a subcortical closed-loop system for detection and suppression of tics in subjects with medically refractory debilitating Tourette Syndrome. The project will use the FDA-approved "Medtronic Percept PC" device, which is an implantable neurostimulator capable of recording neural signals. The study will target the CM nucleus of the thalamus and the aGPi in each brain hemisphere from each subject and we will connect the two leads placed in each brain hemisphere to two Percept devices.
Primary Outcome
The YGTSS is a clinician-rated scale used to assess tic severity over the prior week. It includes a checklist of motor and vocal tics followed by an assessment of the number, frequency, intensity, complexity, and inference of motor tics and phonic tics - scored separately. Each of these dimensions is scored on a 0 to 5 scale. The YGTSS provides three tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25) and the combined Total Tic Severity Score (0 to 50), as well as a separate Impai
Conditions Studied
Interventions
- DEVICE Medtronic Percept Neurostimulator
Study Locations (1)
Florida
- Norman Fixel Institute for Neurological Diseases - University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-06-20 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What the registry record for NCT05371041 still lists
NCT05371041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 86-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Tourette Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Medtronic Percept Neurostimulator is the first listed.
NCT05371041 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05371041 about?
NCT05371041 is a clinical study titled "Tourette Deep Brain Stimulation (DBS) Target Detection & Suppression". The investigators will implant and monitor 8 research subjects with a subcortical closed-loop system for detection and suppression of tics in subjects with medically refractory debilitating Tourette Syndrome. The project will use the FDA-approved "Medtronic Percept PC" device, which is an implantabl...
What is the current status of trial NCT05371041?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 8 participants. The study started on 2022-06-20. Estimated completion is 2026-08-31.
What conditions does trial NCT05371041 study?
This clinical trial studies the following conditions: Tourette Syndrome.
What interventions are being tested in trial NCT05371041?
The interventions under investigation include: Medtronic Percept Neurostimulator (DEVICE).
Who is sponsoring clinical trial NCT05371041?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05371041 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05371041's enrollment target sits among peer trials
8 33rd of 33 higher than 1 of 33 other Tourette Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tourette Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Remote Delivery of a Mindfulness-based Intervention for Tics
RECRUITING · NA
-
Trajectories of Change in Tourette Syndrome
RECRUITING · NA
-
Clinical Characteristics and Temporal Properties of Individual Tics in Persistent Tic Disorder
RECRUITING · NA
-
Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study
RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
-
Repetitive Transcranial Magnetic Stimulation to Reduce Tics
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI